Among the most recurrent are inactivating mutations in chromatin remodelers such as SMARCA4, observed in 5–10% of NSCLC patients, particularly those with KRAS-mutant or smoking-associated tumors [27]. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.